Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Hypothermia claims newborn in Gaza and more babies are at risk, doctor says - 2Europe's powerful Ariane 6 rocket launches Sentinel-1D Earth-observation satellite to orbit (video)
- 3The Craft of Computerized Detox: Individual Trials
- 4U.S. overhauls childhood vaccine schedule, recommends fewer shots
- 5Foreign journalist kidnapped in Iraq: Interior Ministry
- Figure out How to Involve a Brain science Certification in Showcasing
- Winter storm headed for Midwest to Northeast. Here's how much snow to expect.
- Was This Driver Simply Having Some good times Or Behaving Like An Ass?
- EU Council president: Ukraine should receive binding guarantees
- Vote in favor of Your #1 Climbing boots Now
- SF Chinatown's historic Empress of China building being revived into cultural campus
- The Best Internet based Courses for Expertise Improvement
- The Job of a Migration Legal advisor: How They Can Help You
- Nine in 10 German industrial firms expect Iran war to hit business
